Literature DB >> 15022307

Radiographic progression depicted by probability plots: presenting data with optimal use of individual values.

Robert Landewé1, Désirée van der Heijde.   

Abstract

Mesh：

Year:  2004        PMID： 15022307     DOI： 10.1002/art.20204

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  18 in total

Review 1.  Presentation and analysis of radiographic data in clinical trials and observational studies.

Authors:  R Landewé; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission.

Authors:  R Landewé; D van der Heijde; S van der Linden; M Boers
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

3.  Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.

Authors:  X Baraliakos; J Listing; M Rudwaleit; H Haibel; J Brandt; J Sieper; J Braun
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

4.  Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope.

Authors:  Bert Vander Cruyssen; Ilse E A Hoffman; Isabelle Peene; Ann Union; Herman Mielants; Lydie Meheus; Filip De Keyser
Journal:  Ann Rheum Dis       Date:  2006-07-13       Impact factor: 19.103

5.  Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order.

Authors:  A Wanders; R Landewé; A Spoorenberg; K de Vlam; H Mielants; M Dougados; S van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2004-08-05       Impact factor: 19.103

6.  Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis.

Authors:  Shahin Jamal; Kaushik Patra; Edward C Keystone
Journal:  Clin Rheumatol       Date:  2008-12-09       Impact factor: 2.980

7.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Arthritis Rheum       Date:  2011-03

Review 8.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

9.  Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.

Authors:  Pernille Bøyesen; Mari Hoff; Sigrid Odegård; Glenn Haugeberg; Silje W Syversen; Per I Gaarder; Cecilie Okkenhaug; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

10.  Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis.

Authors:  Désirée van der Heijde; Robert Landewé; Annelies Boonen; Steve Einstein; Gertraud Herborn; Rolf Rau; Siegfried Wassenberg; Barbara N Weissman; Carl S Winalski; John T Sharp
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.